Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Vertex Pharmaceuticals Incorporated

< Previous 1 2 3 4 Next >
Vertex Announces U.S. FDA Approval for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 2 Through 5 With Certain Mutations
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex to Present at the Bank of America Securities 2023 Health Care Conference on May 9
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex to Announce First Quarter 2023 Financial Results on May 1
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers CRSP VRTX
Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex’s Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers CRSP VRTX
Vertex Announces Publication in New England Journal of Medicine of Results from Phase 2 Study of Inaxaplin (VX-147)
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Announces FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex to Present at Cowen’s 43rd Annual Health Care Conference on March 7
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex to Announce Fourth Quarter and Full Year 2022 Financial Results on February 7
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 9
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Announces Investigational New Drug (IND) Application for VX-522, mRNA Therapy for People With Cystic Fibrosis, Cleared by FDA
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex and CRISPR Therapeutics to Present at the American Society of Hematology (ASH) Annual Meeting and Exposition
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers CRSP VRTX
Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle (EEV) Therapeutics for Myotonic Dystrophy Type 1 (DM1)
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers TRDA VRTX
Vertex to Participate in Upcoming Investor Conferences
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Announces Partnership with Basketball Hall-of-Famer Alonzo Mourning to Raise Awareness of APOL1-Mediated Kidney Disease (AMKD)
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex to Present New Data on its Portfolio of Cystic Fibrosis Medicines at the 2022 North American Cystic Fibrosis Conference
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Reports Third Quarter 2022 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex to Announce Third Quarter 2022 Financial Results on October 27
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Advances Program Targeting Alpha-1 Antitrypsin Deficiency
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Appoints Jonathan Biller as Chief Legal Officer
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Announces U.S. FDA Approval for ORKAMBI® (lumacaftor/ivacaftor) in Children With Cystic Fibrosis Ages 12 to <24 months
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex to Participate in the Wells Fargo Healthcare Conference on Friday, September 9
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Reports Second Quarter 2022 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Advances VX-548 in Acute and Neuropathic Pain
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex to Announce Second Quarter 2022 Financial Results on August 4
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex to Acquire ViaCyte, With the Goal of Accelerating its Potentially Curative VX-880 Programs in Type 1 Diabetes
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Announces FDA Has Lifted the Clinical Hold on VX-880 Phase 1/2 Clinical Trial for the Treatment of Type 1 Diabetes
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With exagamglogene autotemcel (exa-cel) at the 2022 European Hematology Association (EHA) Congress
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers CRSP VRTX
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.